EGFR and neoplasm: Frequent CN gains were observed in JUN (70% patient tumours, 50% cell lines, 66% PDX models), EGFR (55% patient tumours, 25% cell lines, 33% PDX models) and CDK6 (45% patient tumours, 75% cell lines, 66% PDX models) with notable gains also seen in MET (40% patient tumours, 50% cell lines, 66% PDX models; Fig. 1A).